Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
ANGLE plc ( (GB:AGL) ) has shared an update.
ANGLE plc announced novel research findings using their Parsortix system, which reveals the role of CTC:B cell clusters in cancer progression. This research, conducted by Professor Dario Marchetti’s team, highlights the potential for developing new drugs to target these clusters and suppress cancer metastasis. By demonstrating how B cells and CTC clusters enhance metastatic potential and treatment resistance, the study provides critical insights into cancer metastasis, potentially influencing patient care and treatment strategies. The findings, published in a leading cancer research journal, could lead to increased interest in the Parsortix system for further research and drug discovery in the metastatic pathway.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company that provides innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. Their Parsortix® PC1 System, which is FDA cleared and patent protected, enables comprehensive downstream analysis of blood samples for whole cell imaging, proteomic, genomic, and transcriptomic analysis. ANGLE’s commercial focus is on clinical services, offered through GCLP-compliant laboratories, and diagnostic products including the Parsortix system and associated consumables.
YTD Price Performance: 60.98%
Average Trading Volume: 1,613,563
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £53.22M
For a thorough assessment of AGL stock, go to TipRanks’ Stock Analysis page.
